Biotech Values

[dewophile]

I didn't see that in the slides (haven't listened to the cc), but the proportion of patients in the slides that have the E4 allele was 1% higher in the drug arm (essentially no difference). So the other arms must have had higher proportion of E4 allele vs placebo. So some realized effect in the highest dose arm might be explained at least in part by lower E4 carrier status, but this doesn't explain the 10 mg arm doing better than placebo with what must have been a higher rate of E4 allele carriers.
the trend for worse rate of decline in the low dose cohorts can also potentially be explained by higher E4 carrier status then too